Roche’s Polivy continues its regulatory dance, will head to FDA for a form of blood cancer

[cafead]

via While Roche has previously touted Polivy data for diffuse large B-cell lymphoma (DLBCL), the drug has faced some delays on the regulatory side. But the most recent news from the FDA looks encouraging for the biotech.

article source